Neurocrine Biosciences, Inc. (NBIX)Healthcare | Drug Manufacturers - Specialty & Generic | San Diego, United States | NasdaqGS
135.91 USD
+0.78
(0.577%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 1:31 a.m. EDT
Neurocrine presents a compelling long-term story driven by robust revenue growth of nearly 40 percent and a healthy return on equity, supported by a fortress-like balance sheet and strong cash generation. Despite the company's exceptional fundamentals and a 193 percent gain over the past nine years, the stock currently trades below its 50-day and 200-day moving averages, creating a technical lag that weighs on the short-term outlook. While analysts project significant upside with a mean target well above current prices, the lack of a dividend and recent price weakness suggest patience is required. The options market reflects this tension, with bullish positioning at distant strikes offset by protective puts at near-term levels. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.154901 |
| AutoETS | 0.160254 |
| AutoARIMA | 0.161583 |
| AutoTheta | 0.188218 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 3.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.159 |
| Excess Kurtosis | 1.09 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 1995-12-28 |
| Debt to Equity Ratio | 12.497 |
| Revenue per Share | 33.655 |
| Market Cap | 13,815,141,376 |
| Trailing P/E | 19.81 |
| Forward P/E | 11.37 |
| Beta | 0.40 |
| Profit Margins | 20.91% |
| Website | https://www.neurocrine.com |
As of Oct. 10, 2026, 1:31 a.m. EDT: Speculators are positioning for long-term upside with heavy call open interest at 210 and 230 strikes for 2027, indicating a bullish thesis on the business. However, near-term hedging is evident with significant put open interest at the 160 strike for November 2026, suggesting traders are protecting against a pullback near current levels. Implied volatility remains elevated at the money, reflecting uncertainty around the earnings beat and growth spending concerns.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.0117073655 |
| Address1 | 6,027 Edgewood Bend Court |
| All Time High | 186.12 |
| All Time Low | 1.94 |
| Ask | 146.59 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 1,446,540 |
| Average Daily Volume3 Month | 1,308,107 |
| Average Volume | 1,308,107 |
| Average Volume10Days | 1,446,540 |
| Beta | 0.4 |
| Bid | 124.14 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 36.354 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 135.91 |
| Current Ratio | 1.872 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 136.5699 |
| Day Low | 132.25 |
| Debt To Equity | 12.497 |
| Display Name | Neurocrine Biosciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,655,000 |
| Earnings Call Timestamp Start | 1,793,655,000 |
| Earnings Growth | 0.311 |
| Earnings Quarterly Growth | 0.343 |
| Earnings Timestamp | 1,793,649,600 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | 913,299,968 |
| Ebitda Margins | 0.2707 |
| Enterprise To Ebitda | 15.205 |
| Enterprise To Revenue | 4.116 |
| Enterprise Value | 13,886,940,160 |
| Eps Current Year | 10.18748 |
| Eps Forward | 11.95053 |
| Eps Trailing Twelve Months | 6.86 |
| Esg Populated | 0 |
| Ex Dividend Date | 820,195,200 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 150.2328 |
| Fifty Day Average Change | -14.3228 |
| Fifty Day Average Change Percent | -0.09533737 |
| Fifty Two Week Change Percent | -1.1707366 |
| Fifty Two Week High | 186.12 |
| Fifty Two Week High Change | -50.20999 |
| Fifty Two Week High Change Percent | -0.26977214 |
| Fifty Two Week Low | 122.14 |
| Fifty Two Week Low Change | 13.770004 |
| Fifty Two Week Low Change Percent | 0.11273952 |
| Fifty Two Week Range | 122.14 - 186.12 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 832,858,200,000 |
| Float Shares | 100,351,121 |
| Forward Eps | 11.95053 |
| Forward P E | 11.372718 |
| Free Cashflow | 638,237,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,500 |
| Fullday Change | 0.7799988 |
| Fullday Change Percent | 0.57722104 |
| Fullday Price | 135.91 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.6448 |
| Gross Profits | 2,175,500,032 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01064 |
| Held Percent Institutions | 1.02895 |
| Implied Shares Outstanding | 101,649,181 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://www.neurocrine.com/index.cfm?navid=6 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California. |
| Long Name | Neurocrine Biosciences, Inc. |
| Market | us_market |
| Market Cap | 13,815,141,376 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_32073 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 705,500,032 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 14,411,820,882 |
| Number Of Analyst Opinions | 29 |
| Open | 133.94 |
| Operating Cashflow | 898,099,968 |
| Operating Margins | 0.2219 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.27 |
| Phone | 858 617 7600 |
| Previous Close | 135.13 |
| Price Eps Current Year | 13.340885 |
| Price Hint | 2 |
| Price To Book | 3.7385159 |
| Price To Sales Trailing12 Months | 4.09471 |
| Profit Margins | 0.20910999 |
| Quick Ratio | 1.46 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.41379 |
| Region | US |
| Regular Market Change | 0.7799988 |
| Regular Market Change Percent | 0.57722104 |
| Regular Market Day High | 136.5699 |
| Regular Market Day Low | 132.25 |
| Regular Market Day Range | 132.25 - 136.5699 |
| Regular Market Open | 133.94 |
| Regular Market Previous Close | 135.13 |
| Regular Market Price | 135.91 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 1,506,669 |
| Return On Assets | 0.11704001 |
| Return On Equity | 0.22089 |
| Revenue Growth | 0.395 |
| Revenue Per Share | 33.655 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 101,649,181 |
| Shares Percent Shares Out | 0.057600003 |
| Shares Short | 5,853,128 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,056,144 |
| Short Name | Neurocrine Biosciences, Inc. |
| Short Percent Of Float | 0.0748 |
| Short Ratio | 4.67 |
| Source Interval | 15 |
| State | CA |
| Symbol | NBIX |
| Target High Price | 253.0 |
| Target Low Price | 150.0 |
| Target Mean Price | 206.81139 |
| Target Median Price | 213.0 |
| Total Cash | 389,800,000 |
| Total Cash Per Share | 3.835 |
| Total Debt | 461,600,000 |
| Total Revenue | 3,373,900,032 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 6.86 |
| Trailing P E | 19.811953 |
| Trailing Peg Ratio | 0.2824 |
| Triggerable | 1 |
| Two Hundred Day Average | 147.0983 |
| Two Hundred Day Average Change | -11.188293 |
| Two Hundred Day Average Change Percent | -0.07605998 |
| Type Disp | Equity |
| Volume | 1,506,669 |
| Website | https://www.neurocrine.com |
| Zip | 92,130 |